Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04472767 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated July 1, 2026 (before its estimated October 1, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary completion pushed from Jun 1, 2026 to Oct 1, 2026v11
  2. 3 versions Re-verified since Apr 3, 2025, no change to tracked fieldsv8-v10
  3. Primary completion date: Dec 31, 2023 to Jun 1, 2026 Completion date: Sep 1, 2025 to Sep 1, 2027v7 Show 1 more changeShow less
    • Completion date: Sep 1, 2025 to Sep 1, 2027
  4. Primary completion date: Mar 1, 2023 to Dec 31, 2023v6
  5. Primary completion date: Mar 1, 2022 to Mar 1, 2023 Completion date: Sep 1, 2024 to Sep 1, 2025v5 Show 1 more changeShow less
    • Completion date: Sep 1, 2024 to Sep 1, 2025
Show 3 earlier versionsHide 3 earlier versions
  1. Eligibility criteria revisedv4 See this version in full on ClinicalTrials.gov ↗
  2. Eligibility criteria revisedv3 See this version in full on ClinicalTrials.gov ↗
  3. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Sep 1, 2020 to Aug 7, 2020 · Site details revisedv2 Show 2 more changesShow less
    • Start date changed from estimate of Sep 1, 2020 to Aug 7, 2020
    • Site details revised
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a phase 2 single-arm, open-label clinical trial determining efficacy of cabozantinib in combination with ipilimumab/nivolumab and transarterial chemoembolization (TACE) in subjects with hepatocellular carcinoma (HCC). These are subjects who are not candidates for curative intent treatment.
Trial Details
NCT Number NCT04472767
Lead Sponsor University of California, Irvine
Collaborators: Exelixis
Conditions Hepatocellular Carcinoma, HCC
Enrollment 35 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov